[1]郑洋洋,丁锦希,李佳明,等.高值耗材实施集中带量采购的主要障碍及对策研究[J].卫生经济研究,2021,38(4):35-38.
　ZHENG Yang-yang,DING Jin-xi,LI Jia-ming,et al.Research on the Main Obstacles and Countermeasures of Centralized Quantity Purchase of High Value Medical Consumables[J].Journal Press of Health Economics Research,2021,38(4):35-38.
点击复制

高值耗材实施集中带量采购的主要障碍及对策研究
分享到：

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
38
期数:
2021年4期
页码:
35-38
栏目:
药械管理
出版日期:
2021-03-30

文章信息/Info

Title:
Research on the Main Obstacles and Countermeasures of Centralized Quantity Purchase of High Value Medical Consumables
作者:
郑洋洋1; 丁锦希1; 李佳明1; 吴秋婷1
1.中国药科大学国际医药商学院，江苏 南京 211198
Author(s):
ZHENG Yang-yang; DING Jin-xi; LI Jia-ming; WU Qiu-ting
School of International Pharmaceutical Business,China Pharmaceutical University, Nanjing Jiangsu 211198,China
关键词:
高值耗材; 集中带量采购; 替代效应; 规模效应
Keywords:
high value medical consumables;  centralized quantity purchase; substitution effect; scale effect
分类号:
R19
文献标志码:
A
摘要:
为有效解决高值耗材价格虚高等问题，国家提出将药品集中带量采购经验推广至高值耗材领域。然而，高值耗材与药品之间存在较大差异，实施集中带量采购存在缺少一致性评价、品牌粘性强等障碍。对此，应在保证其质量和临床使用效果的前提下，从高值耗材的特殊性角度切入，通过采用“精细分组+构建指标体系”替代技术方案、建立科学完善的市场份额分配方案等方式，有效控制高值耗材价格。
Abstract:
In order to effectively solve the problem of false and high prices of high value medical consumables, the state proposes to extend the experience of drug centralized quantity purchase to the field of high value medical consumables. However, there are great differences between high value medical consumables and drugs, and there are some obstacles in the implementation of high value medical consumables centralized quantity purchase such as lack of consistent evaluation, strong brand stickiness and so on. Therefore,on the premise of ensuring quality and clinical application effect, from the point of view of the specificity of high value medical consumables, we should adopt " fine grouping + construction index system" as the succedaneous technical scheme and establish a scientific and perfect market share distribution scheme to control the price of high value medical consumables effectively.

参考文献/References:

[1] 张雅娟，方来英.药品集中采购制度的发展与改革研究[J].中国药房，2020，31（21）：2561-2565.
[2] 万楚川，卢梦情，徐霭琳，等.法国仿制药替代计划对我国的启示[J].中国新药杂志，2020，29（8）：869-874.
[3] 冯霄婵，杨悦.美国鼓励仿制药替代使用政策与措施研究[J].中国卫生政策研究，2019，12（2）：7-14.
[4] Anna Borisovna Khmelnitskaya.Shapley value for constant-sum games[J].International journal of game theory,2003,32(2): 223-227.
[5] 2018年我国阿卡波糖销售额及市场份额分析[EB/OL].[2020-02-20].http://data.chinabao gao.com/yiyao/2020/02204P2M2020.html.
[6] 关于公布全国药品集中采购中选结果的通知[EB/OL].[2020-01-21]. http://www.yyzbsw.sh.cn/gjsdcg/2020/01/21/9270.shtml.
[7] 陈烨，丁锦希，郝丽，等.集中带量，还是挂网议价采购——生物类似物采购模式研究[J].中国医药工业杂志，2020，51（4）：539- 544.
[8] 杜雪，马珺，黎雯霞. 药品带量采购存在的问题与对策分析[J].卫生经济研究，2020，37（8）：42-49.
[9] 钱程，鲍海. 电力市场下边际成本计算方法的解读[J].电力系统保护与控制，2010，38（17）：8-10.
[10] 张红岩, 张文杰.集中招标采购对投标人的机制设计研究[J].中国软科学，2008（5）：129-135.
[11] 关于国家组织药品集中采购试点扩大区域范围答记者问[EB/OL].[2019-09-25].http://www.smpaa.cn/gjsdcg/2019/09/25/9016.shtml.
[12] 丁锦希，董锐，李伟，等.我国医用耗材采购竞价分组方案初探[J].中国卫生政策研究, 2017,10(12):27-32.
[13] 国家食品药品监督管理总局.医疗器械临床试验质量管理规范[EB/OL].[2016-03-23].https://www.nmpa.gov.cn/xxgk/fgwj/bmgzh/20160323141701747.html.
[14] CFDA南方医药经济研究所.我国医用高值耗材行业市场研究报告[EB/OL].[2017-04-20].https://www.menet.com.cn/pdf/20170 4201548364836.pdf.
[15] 罗诚祖.53例医用耗材质量不良事件分析[J].解放军医院管理杂志，2014，21（2）：135-148.

相似文献/References:

[1]傅鸿鹏,胡宗铃.高值医用耗材的政策框架和管理体系[J].卫生经济研究,2019,(07):3.
　FU Hong-peng,HU Zong-ling.Policy Framework and Management System for High Value Medical Consumables[J].Journal Press of Health Economics Research,2019,(4):3.
[2]周菁菁,谈在祥.国家组织冠脉支架集中带量采购的实施情况及建议[J].卫生经济研究,2021,38(11):3.
　ZHOU Jing-jing,TAN Zai-xiang.Implementation and Suggestions of Centralized Volume-based Procurement of Coronary Stent by National Organization[J].Journal Press of Health Economics Research,2021,38(4):3.
[3]赵予涵,林燕铭,谭艳芬.高值医用耗材治理背景下老年性白内障手术费用研究[J].卫生经济研究,2022,39(1):40.
　ZHAO Yu-han,LIN Yan-ming,TAN Yan-fen.Study on the Cost of Senile Cataract Surgery Under the High-value Medical Consumables Governance[J].Journal Press of Health Economics Research,2022,39(4):40.
[4]冷楠楠,邱英鹏,赵羽西,等.冠脉支架集中带量采购对医疗服务供给的潜在影响分析[J].卫生经济研究,2022,39(5):1.
　LEN Nan-nan,QIU Ying-peng,ZHAO Yu-xi,et al.Analysis of the Potential Impact of the Policy of Centralized Procurement of Coronary Stents on the Provision of Medical Services[J].Journal Press of Health Economics Research,2022,39(4):1.
[5]蒋范黎,肖 月,赵羽西,等.集采背景下经皮冠脉支架植入术成本测算及建议[J].卫生经济研究,2022,39(5):4.
　JIANG Fan-li,XIAO Yue,ZHAO Yu-xi,et al.The Cost Calculation and Analysis of Percutaneous Coronary Intervention under the Background of Centralized Procurement of Stents[J].Journal Press of Health Economics Research,2022,39(4):4.
[6]罗婷婷,王秀英,吴伟旋,等.医院不计价及打包收费耗材的管理现状及对策[J].卫生经济研究,2022,39(5):91.
　LUO Ting-ting,WANG Xiu-ying,WU Wei-xuan,et al.Management Status and Improvement Suggestions of Non-priced and Packaged Charging Consumables[J].Journal Press of Health Economics Research,2022,39(4):91.
[7]黄晓青,王煜昊,王丽娜,等.医用耗材集采背景下按病种分值付费优化方案研究 ——以冠状动脉支架为例[J].卫生经济研究,2022,39(10):16.
　HUANG Xiaoqing,WANG Yuhao,WANG Lina,et al.Research on Policy Optimization of Diagnosis-Intervention Packet Based the Volume-Based Procurement of Medical Comsumables ——Taking Coronary Stents as an Example[J].Journal Press of Health Economics Research,2022,39(4):16.
[8]孙李丽,毛 英,张馨怡,等.国家集中带量采购冠脉支架对住院费用的影响研究[J].卫生经济研究,2023,40(5):55.
　SUN Lili,MAO Ying,ZHANG Xinyi,et al.Study on the Effect of National Centralized Volume-based Procurement of Coronary Stents on Hospitalization Costs[J].Journal Press of Health Economics Research,2023,40(4):55.
[9]李 洁,周胜男,孙源源.基于政策工具理论的中成药集中带量采购政策设计研究[J].卫生经济研究,2023,40(6):13.
　LI Jie,ZHOU Shengnan,SUN Yuanyuan.Study on the Policy Design of Centralized Volume-based Procurement of Chinese Patent Medicine Based on the Policy Tools Theory[J].Journal Press of Health Economics Research,2023,40(4):13.
[10]徐露露,张 钿,陈井婵,等.医保战略性购买对医药企业创新的影响研究[J].卫生经济研究,2023,40(12):7.
　XU Lulu,ZHANG Tian,CHEN Jingchan,et al.Study on the Impact of Strategic Purchase of Medical Insurance on Innovation of Pharmaceutical Enterprises[J].Journal Press of Health Economics Research,2023,40(4):7.

更新日期/Last Update: 2021-03-30